secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIRA PHARMACEUTICALS, INC. (MIRA)
CIK:        0001904286
Form:       8-K
Filed at:   2026-07-06T13:00:15+00:00
Accession:  0001493152-26-032091
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MIRA's SKNY-1 shows favorable oral bioavailability, brain penetration in preclinical studies
--------------------------------------------------------------------------------

- Optimized oral formulation of SKNY-1 demonstrated favorable oral bioavailability and reproducible systemic exposure in preclinical PK study.
- Robust brain penetration and substantial liver exposure observed; peak plasma concentrations at 6-12 hours support once-daily oral dosing.
- Findings complement prior efficacy studies showing weight reduction, lean mass preservation, and reduced compulsive feeding/nicotine-seeking.
- SKNY-1 designed with biased CB1 modulation, CB2 agonism, and selective MAO-B inhibition; no anxiety-like behavior in preclinical model.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1904286/000149315226032091/0001493152-26-032091-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1904286/000149315226032091/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-032091

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer